The Burden of Respiratory Syncytial Virus Infection in the Young最新文献

Disease Severity in Respiratory Syncytial Virus Infection: Role of Viral and Host Factors 呼吸道合胞病毒感染的疾病严重程度:病毒和宿主因素的作用

The Burden of Respiratory Syncytial Virus Infection in the Young Pub Date : 2019-10-30 DOI: 10.5772/intechopen.88782

J. Legg

引用次数: 0

Hurdles in Vaccine Development against Respiratory Syncytial Virus 呼吸道合胞病毒疫苗开发的障碍

The Burden of Respiratory Syncytial Virus Infection in the Young Pub Date : 2019-08-01 DOI: 10.5772/INTECHOPEN.87126

M. Shafique, M. Zahoor, Muhammad Arshad, B. Aslam, A. Siddique, M. Rasool, M. Qamar, M. Usman

{"title":"Hurdles in Vaccine Development against Respiratory Syncytial Virus","authors":"M. Shafique, M. Zahoor, Muhammad Arshad, B. Aslam, A. Siddique, M. Rasool, M. Qamar, M. Usman","doi":"10.5772/INTECHOPEN.87126","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.87126","url":null,"abstract":"Respiratory syncytial virus (RSV) infection is a major cause of severe respiratory disease in infants and young children worldwide and also forms a serious threat for the elderly. Vaccination could significantly relieve the burden of the RSV disease. However, unfortunately there is no licensed vaccine available so far. This is partly due to disastrous outcome of a clinical trial of formalin-inactivated RSV (FI-RSV) in children in 1960s; leading to enhanced respiratory disease upon natural infection. These findings contributed significantly to the delay of RSV vaccine development. Other key obstacles in development of RSV vaccine such as a peak of severe disease at 2–3 months of age, challenging biochemical behavior of key vaccine antigens and dependence on animal models that may not truly reflect human disease processes. These challenges could be overcome through maternal immunization, structure-based engineering of vaccine antigens, the design of a novel platform for safe infant immunization, and the development of improved animal models. Currently, several vaccine candidates are in pre-clinical and clinical trials targeting the diverse age groups; young children or older adults from the infection or can reduce incidence, mortality and morbidity among the RSV infected individuals.","PeriodicalId":366789,"journal":{"name":"The Burden of Respiratory Syncytial Virus Infection in the Young","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132103236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Respiratory Syncytial Virus Infections among Children with Congenital Heart Disease 先天性心脏病患儿呼吸道合胞体病毒感染

The Burden of Respiratory Syncytial Virus Infection in the Young Pub Date : 2019-05-31 DOI: 10.5772/intechopen.85552

Maja Daurach, I. Michel-Behnke

引用次数: 3

Resolving the Debate on RSV Prophylaxis in Late Preterm Infants 解决关于晚期早产儿RSV预防的争论

The Burden of Respiratory Syncytial Virus Infection in the Young Pub Date : 2019-03-21 DOI: 10.5772/INTECHOPEN.85073

B. Paes, B. Rodgers-Gray, X. Carbonell-Estrany

引用次数: 2

RSV: Available Prophylactic Options and Vaccines in Clinical Trials RSV:临床试验中可用的预防选择和疫苗

The Burden of Respiratory Syncytial Virus Infection in the Young Pub Date : 2019-03-01 DOI: 10.5772/INTECHOPEN.84851

D. Linfield, F. Rezaee

{"title":"RSV: Available Prophylactic Options and Vaccines in Clinical Trials","authors":"D. Linfield, F. Rezaee","doi":"10.5772/INTECHOPEN.84851","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.84851","url":null,"abstract":"Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory infection (ALRI)-related hospitalization in children worldwide, and a source of morbidity and mortality in high-risk adults. There are strong associations between RSV, persistent wheezing and childhood asthma. Despite extensive research, no effective treatment is available aside from supportive care. The trial of a formalin-inactivated RSV vaccine in the 1960s resulted in priming the severe illness upon natural infection. Palivizumab, a monoclonal antibody approved for RSV prophylaxis in high-risk infants, has only moderately decreased hospital admissions due to RSV infection. Live-attenuated, vector, and protein-based vaccine candidates are being investigated in many clinical trials. Developing a vaccine remains challenging due to finding the right balance between adequate immunogenicity and attenuation of vaccine. Here we review the clinical significance of RSV in infants, young children, high-risk adults, elderly population, pregnant women; clinical manifesta-tions and consequences of RSV infection; the pharmacologic strategies currently available, the current stages of RSV vaccine clinical trials, different strategies, and major hurdles in the development of an effective RSV vaccine.","PeriodicalId":366789,"journal":{"name":"The Burden of Respiratory Syncytial Virus Infection in the Young","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115534887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1